UK-based Bioniq secures €13.7M to disrupt the dietary supplement market

London-based Bioniq, a company that claims to make the world’s most personalised supplements based on blood biomarker data, has announced the close of a $15M (nearly €13.74M) Series B funding round. The company’s valuation now stands at $75M (nearly €68.73M).

The oversubscribed round was led by principal investors HV Capital and Unbound.

David Kuczek, General Partner at HV Capital, says, “Bioniq’s exceptional growth is a testament to its innovative approach for high-quality personalised health solutions that professional athletes across the world rely on.”

“With sales from across 60 countries with the majority coming from North America, the most important market for health solutions globally, Bioniq is well-positioned to continue its trajectory of rapid expansion.”

Capital utilisation

The funds will be used to expand Bioniq’s global market share by continuing to disrupt the dietary supplements market.

Key focus areas include product development, integrating a global laboratory network, expanding market, operational, and human resources in the US and the Middle East, and implementing a corporate platform for medical, wellness, and athletic institutions.

Shravin Mittal, CEO of Unbound, says, “Bioniq’s innovative approach to nutrition is based on the idea that everyone has different nutritional needs and deficiencies, and that generic multivitamins are not enough to address them.”

“We are impressed by Bioniq’s vision and technology, and we believe that they are disrupting the supplement industry with their personalized and science-based approach. We are excited to support them as they grow and scale their business.”

World’s most personalised supplements

Launched in 2019, Bioniq offers AI-driven personalised supplements based on blood test data. With the largest proprietary biochemical database from customers across five continents, Bioniq has created formulas for over 100,000 users, tailored to their individual nutrient deficiencies.

Bioniq offers two distinct approaches to personalised health optimisation. Bioniq PRO provides high-level personalisation by incorporating blood biomarker data, allowing users to upload existing bloodwork or book tests through partner labs. This data is used to tailor daily supplements and includes consultations with a Registered Dietitian. 

For a more accessible option, Bioniq GO uses a questionnaire to recommend supplement blends based on the AI algorithm and previous users’ blood data. Both options leverage Bioniq’s extensive proprietary biochemical database to optimise individual health.

Bioniq’s Swiss-made, pharmaceutical-grade supplements are custom-formulated with precise micro-dosing to meet individual needs. Each formula includes a mix of antioxidants, vitamins, minerals, phytonutrients, amino acids, and prebiotic fiber. 

Delivered in patented prebiotic guar granules instead of traditional pills, these supplements enhance nutrient absorption by mimicking natural digestion.

The company claims to have seen significant growth, especially in the US, which now makes up over 50 per cent of its customer base, with some regions growing over 500% in the last two quarters.

Bioniq’s data-driven approach and quantifiable results have attracted partnerships with leading health and sports institutions such as Lanserhof and UFC and have become the preferred choice for top athletes like Manchester United’s Diogo Dalot and former NBA All-Star Andrei Kirilenko.

Vadim Fedotov, co-founder and CEO of Bioniq, says, “We’ve entered a new era in nutritional supplementation over the last six years, where it’s become clear that one-size-fits-all solutions are simply inefficient.”

“Everyone’s health journey is unique and fluid. Customers need advanced, adaptable products that provide evolving support for personal health goals. Our AI-driven approach and extensive biochemical database allow us to create customised supplements that provide quantifiable results and cater to individuals’ specific needs.”

“Beyond meeting consumer demand, we’re setting a new standard in the industry by making the process and results transparent to the users,” adds Fedotov.